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Kootte et al. show that fecal microbiota
transplantation from lean donors to
obese patients with metabolic syndrome
improves insulin sensitivity, a transient
effect associated with changes in
microbiota composition and fasting
plasma metabolites. Baseline fecal
microbiota composition in recipients
predicts the response to lean donor fecal
microbiota transplantation.
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The intestinal microbiota has been implicated in
insulin resistance, although evidence regarding
causality in humans is scarce. We therefore studied
the effect of lean donor (allogenic) versus own (autol-
ogous) fecal microbiota transplantation (FMT) to
male recipients with the metabolic syndrome.
Whereas we did not observe metabolic changes at
18 weeks after FMT, insulin sensitivity at 6 weeks
after allogenic FMT was significantly improved,
accompanied by altered microbiota composition.
We also observed changes in plasma metabolites
such as g-aminobutyric acid and show that meta-
bolic response upon allogenic FMT (defined as
improved insulin sensitivity 6 weeks after FMT) is
dependent on decreased fecal microbial diversity at
baseline. In conclusion, the beneficial effects of
lean donor FMT on glucose metabolism are associ-
ated with changes in intestinal microbiota andCell Mplasma metabolites and can be predicted based on
baseline fecal microbiota composition.
INTRODUCTION
The worldwide burden of obesity and related illnesses such as
diabetes mellitus warrants new therapeutical modalities, as
current therapies such as lifestyle changes and antidiabetic
agents are insufficiently capable of reducing morbidity and
mortality rates (Cefalu et al., 2015). During the last decade,
changing the composition of intestinal microbiota has gained
attention as a novel therapeuticmodality to improve insulin sensi-
tivity (Khan et al., 2014). Several lines of evidence have indicated
that thebacterial compositiondiffers between leanandobesean-
imals (Ley et al., 2005), but also that gut microbial composition
may reflect an aberrant metabolic function including altered
digestion of dietary products (Turnbaugh et al., 2006). Finally,
these animal studies have suggested a causal relation since the
adverse phenotype is transferable via fecal transplantation
(B€ackhed et al., 2004; Turnbaugh et al., 2006). Although manyetabolism 26, 611–619, October 3, 2017 ª 2017 Elsevier Inc. 611
Table 1. Baseline Characteristics
Autologous
FMT (n = 12)
Allogenic
FMT (n = 26) p Value
Male gender (%) 100 100 1.000
Age (years) 54 [49–58] 54 [49–60] 0.914
BMI (kg/m2) 35.8 [33.1–40.4] 33.8 [32.5–35.7] 0.093
Waist
circumference (cm)
121 [115–130] 120 [111–127] 0.297
Blood pressure:
systolic (mmHg)
148 [134–162] 141 [132–154] 0.243
Blood pressure:
diastolic (mmHg)
94 [83–105] 90 [78–97] 0.218
Fasting glucose
(mmol/L)
5.9 [5.5–6.4] 5.5 [5.3–6.1] 0.187
HbA1c (mmol/mol) 43 [36–46] 40 [36–42] 0.218
Insulin (pmol/L) 107 [80–159] 121 [93–143] 0.722
HOMA-IR 4.8 [3.5–6.9] 4.8 [3.7–6.0] 0.963
Cholesterol: total
(mmol/L)
5.5 [4.8–6.6] 5.5 [4.8–6.6] 0.865
Cholesterol: LDL
(mmol/L)
3.7 [3.0–4.8] 3.9 [3.2–4.5] 0.914
Cholesterol: HDL
(mmol/L)




1.3 [1.1–1.8] 1.2 [0.9–1.7] 0.485
Baseline characteristics for patients randomized for autologous and
allogenic (both one and two) treatment(s), expressed as medians and
interquartile ranges in brackets. p < 0.05 was considered significant.
See also Table S1. BMI, body mass index; FMT, fecal microbiota trans-
plantation; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein;
HOMA-IR, homeostatic model assessment – insulin resistance; LDL,
low-density lipoprotein.observational studies have suggested correlations between
alteredmicrobiota composition andmetabolism in humans, cau-
sality has been difficult to prove (Smits et al., 2013). In this
respect, we have previously shown in a small pilot study that
transplantation of lean donor fecal microbiota into obese males
with metabolic syndrome resulted in improved glucose meta-
bolism, which was associated with alterations in intestinal micro-
biota composition in both fecal and duodenal samples (Vrieze
et al., 2012). These findings prompted us to study the short-
and long-term effect of lean donor fecal microbiota transplanta-
tion (FMT) on gut microbiota composition in a larger group of
male metabolic syndrome subjects and dissect the underlying
pathophysiology of insulin resistance by relating intestinal micro-
biota changes to various markers of metabolism. Moreover, we
tried to unravel whether specific characteristics of fecal micro-
biota composition at baseline can explain why some metabolic
syndrome subjects improve in insulin sensitivity upon lean donor
FMT treatment (so-calledmetabolic responders), whereasothers
do not (non-responders).
RESULTS AND DISCUSSION
In line with several recent observational studies that have sup-
ported a role for the intestinal microbiota in metabolic processes612 Cell Metabolism 26, 611–619, October 3, 2017(Thaiss et al., 2016; Zhernakova et al., 2016), and in accordance
with our previous pilot study (Vrieze et al., 2012), we report that
altering intestinal microbiota composition by infusion of healthy
lean donor feces has a (short-term) beneficial impact on periph-
eral insulin sensitivity inmetabolic syndrome patients. In contrast
to animal studies, this effect on insulin-mediated glucose uptake
was not associated with changes in (post-prandial) incretins or
bile acids (Sayin et al., 2013; Wichmann et al., 2013). Other ob-
servations point toward a regulatory role of plasma metabolites
that are derived from diet and converted by intestinal microbiota
in insulin-resistant obese males (Guasch-Ferré et al., 2016).
Although the overall metabolic effects of lean donor FMT are
modest and show a wide variety between patients, our data do
suggest that changes in plasma metabolites (predominantly
amino acids), as a consequence of the altered intestinal micro-
biota composition, might be one explanation for the beneficial
effects of lean donor FMT on peripheral insulin sensitivity.
Inclusion
We included 44 male metabolic syndrome subjects, of whom 6
were excluded (three due to pathology of the proximal gastroin-
testinal tract for which immediate treatment was warranted,
found during the first gastroduodenoscopy [two ulcus ventriculi
and one Barrett esophagus with dysplasia]; one subject with-
drew from the study after the first treatment week; and two
subjects were excluded due to technical difficulties with several
clinical measurements). Therefore, 38 subjects were enrolled in
this study and were randomly distributed over all treatment
groups (Tables 1 and S1). We found no differences in baseline
characteristics between recipients of autologous and allogenic
FMT. We included 11 healthy lean donors, who provided their
fresh feces for the metabolic syndrome subjects randomized
for allogenic FMT (n = 26). Seven lean donors provided feces
for multiple metabolic syndrome subjects with a range of two
to five recipients per single lean donor, while four lean donors
provided feces for one allogenic FMT. Throughout the follow-
up period, there were no serious adverse events or adverse
changes in plasma biochemistry.
Long-Term Effects of Lean Donor FMT
We found that duodenal and fecal microbiota composition at
18 weeks after allogenic FMT was similar to baseline (Figures
1A and 1B). In line, neither single nor repeated allogenic FMT
had significant effects on hepatic (expressed as insulin-medi-
ated suppression of endogenous glucose production; EGP) or
peripheral insulin sensitivity (expressed as rate of glucose disap-
pearance; Rd) at 18 weeks (Figure S1). Weight (plasma and
fecal), short-chain fatty acids (SCFAs), and fasting plasma
metabolites (Figure S2) were not affected. The lack of long-
term clinical effects (both on insulin sensitivity and plasma me-
tabolites) at 18 weeks after allogenic FMT in our study is in line
with previous findings on transient donor bacterial strain engraft-
ment and the presence of a personal fecal core microbiome (Li
et al., 2016). In this regard, it is likely that the host immune system
develops resilience, which, in combination with the adherence of
one’s own lifestyle, including diet (Zeevi et al., 2015), could
explain the return of intestinal microbiota composition to the
baseline situation and the magnitude of metabolic response

































Figure 1. Changes in Duodenal and Fecal Microbiota Composition after Autologous and Allogenic FMT
(A) Biplot of redundancy analysis (RDA axis 1 versus axis 2) of duodenal microbiota data, constrained by autologous and allogenic treatment variables in time
(0, 6, and 18 weeks).
(B) Biplot of redundancy analysis (RDA axis 1 versus axis 2) of fecal microbiota data, constrained by autologous and allogenic treatment variables in time (0, 6, and
18 weeks). Also, baseline fecal microbiota composition in lean FMT donors (n = 11) is depicted.
FMT, fecal microbiota transplantation.Short-Term Effects of Lean Donor FMT: Insulin
Sensitivity and Post-prandial Metabolism
As we did not observe long-term changes in these major
outcome parameters, we focused on changes between weeks
0 and 6 and found that allogenic FMT did result in altered
duodenal and fecal microbiota composition at 6 weeks (Figures
1A and 1B). This was associated with improved peripheral
insulin sensitivity at week 6 (from 25.8 [19.3–34.7] to 28.8
[21.4–36.9] mmol kg1 min1, p < 0.05), whereas autologous
FMT had no effect (from 22.5 [16.9–30.2] to 20.8 [17.6–
29.5] mmol kg1 min1, n.s.) (Figure 2; Table S2). The change in
peripheral insulin sensitivity in the allogenic FMT group was
accompanied by a small but significant decrease in glycated
hemoglobin (HbA1c) at 6 weeks (39.5 [36.0–41.0] to 38.0 [34.0–
41.0] mmol/mol, p < 0.01). Other metabolic parameters (e.g.,
weight, caloric intake, and resting energy expenditure [REE])
were not affected (Tables S2 and S3). Although the results
were more variable than in our previous smaller study, we were
able to reproduce this previous finding of short-term beneficial
changes on peripheral insulin sensitivity upon allogenic FMT
(Vrieze et al., 2012). These data concur with our previous data
that insulin resistance in obese subjects is characterized by a
more pronounced decrease in peripheral insulin sensitivity,
whereas hepatic insulin sensitivity is affected to a lesser and
more variable extent (ter Horst et al., 2015). Moreover, upon
administration of insulin-sensitizing medication, peripheral insu-
lin sensitivity improved significantly more than hepatic insulin
sensitivity (Serlie et al., 2007). In line, we could discern that
approximately half of all subjects treated by allogenic FMT
showed a clinically relevant improvement at 6 weeks. This
modest therapeutic effect and large variability on whole-body
glucose metabolism upon targeted intestinal microbiota inter-
vention is less pronounced than in mice (B€ackhed et al., 2004),but aligns with our previous publications on themetabolic effects
of oral antibiotics to specifically alter intestinal microbiota
composition (Vrieze et al., 2014; Reijnders et al., 2016). With
regard to post-prandial metabolism, the allogenic FMT group
showed an increased post-prandial rise in plasma triglycerides
(incremental area under the curve [iAUC] = 91 [52–129] to 115
[77–146] mM/min, p < 0.05) between weeks 0 and 6. Other
markers such as glucose and enteroendocrine hormones (e.g.,
GLP-1, GIP, and PYY) were not influenced by allogenic FMT
(data not shown). As was described in previous reports, we
found (minor) changes in fecal bile acids (predominantly cholate)
(Weingarden et al., 2014) upon allogenic FMT. Although allo-
genic FMT did not affect fasting and post-prandial total plasma
bile acid concentrations, allogenic FMT significantly increased
fecal cholate excretion (both for fecal concentration and fecal
excretion, p < 0.05) (Figure S3).
Short-Term Effects of Lean Donor FMT: SCFAs,
Intestinal Microbiota, and Plasma Metabolites
Fasting plasma SCFA levels did not change upon allogenic FMT,
and in contrast to our previous study (Vrieze et al., 2012), we did
not observe significant changes in fecal butyrate levels (butyrate
from 13 [6–27] to 20 [13–27] mmol/g feces, p = 0.096) (Table S3).
Fecal acetate levels, however, were significantly increased
from 62 [43–89] to 85 [61–105] mmol/g feces (p < 0.05) after allo-
genic FMT, whereas fecal proprionate was borderline signifi-
cantly altered (from 23 [16–35] to 28 [22–60] mmol/g feces, p =
0.062). Subsequent microbiota analyses showed that allogenic
treatment resulted in significantly altered duodenal bacterial
species including Bifidobacterium pseudolongum, previously
mentioned as a potential probiotic that produces acetate from
dietary carbohydrates (Figure 3A) (Pokusaeva et al., 2011). In
line with our findings of increased fecal acetate upon allogenicCell Metabolism 26, 611–619, October 3, 2017 613
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Figure 2. Changes in Hepatic and Peripheral Insulin Sensitivity between Weeks 0 and 6
This figure shows changes in insulin sensitivity between weeks 0 and 6 for both the autologous and allogenic treatment group. Insulin sensitivity is described as
percentage suppression of EGP as a marker of hepatic insulin sensitivity (A–C), as well as Rd as a marker of peripheral insulin sensitivity (D–F). Grouped data are
expressed as box-and-whisker plots, whereas the spaghetti plots show individual data. p < 0.05 was considered significant. See also Table S2. EGP, endog-
enous glucose production; FMT, fecal microbiota transplantation.FMT, fecal acetate levels are inversely related to insulin resis-
tance in humans (Yamaguchi et al., 2016). Several fecal bacterial
species that were different between autologous and allogenic
FMT have been linked to human metabolism (Figure 3B). These
include the lactate-producing Lactobacillus salivarius (Mes-
saoudi et al., 2013) and butyrate-producing Butyrivibrio (de la
Cuesta-Zuluaga et al., 2017), Clostridium symbiosum (O’Keefe
et al., 2015), and Eubacterium species (Vrieze et al., 2012;
Udayappan et al., 2016). Therewere no differences in fecalmicro-
bial diversity (Shannon index) between baseline and 6 weeks
(allogenic FMT group from 5.9 [5.8–6.0] to 6.0 [5.8–6.1], p =
0.493; autologous FMT group from 5.9 [5.8–6.1] to 6.0 [5.8–6.1],
p = 0.239). Since both our smaller pilot study (Vrieze et al., 2012)
and the current study showed a significant clinical effect of lean
donor FMT on peripheral insulin sensitivity, we conclude that
the differential presence of either acetate or butyrate producers
in donor feces as well as sample size may both account for the
observed differences. Although the driving factors of donor
bacterial strain engraftment are currently unknown, we speculate
that the level of metabolic response might be due to donor-host
interactions. Whether and to what extent adding a standard die-
tary intervention, together with better matching of donors with
hosts, could work synergistically on beneficial gut microbiota
changes and metabolic response require further study.
With respect to other fasting plasma metabolites, intestinal
microbiota have recently been linked to altered (branched chain)
amino acid production in relation to dietary composition (Peder-614 Cell Metabolism 26, 611–619, October 3, 2017sen et al., 2016; Sonnenburg and B€ackhed, 2016). We observed
significant changes in 30 metabolites associated with either
allogenic FMT (positive weight, n = 17) or autologous FMT (nega-
tive weight, n = 13) (Figure 3C). Whereas allogenic FMT was
mostly associated with changes in amino acid concentrations,
autologous FMT was mostly associated with changes in
oxidative stress and lipid-related metabolites. Among others,
allogenic FMT resulted in changes in amino acids such as g-ami-
nobutyric acid (GABA), tryptophan, and kynurenine (involved in
serotonin metabolism), as well as phenylalanine. In particular,
we found that GABA levels showed the strongest relation with
allogenic FMT at 6 weeks. Indeed, GABA has been associated
with control of metabolism in murine models (Meng et al.,
2016). In this regard, the observed change in Lactobacillus brevis
might be of specific interest, since this bacterial species has
been linked to GABA production (Yunes et al., 2016) and its
suppletion in insulin-resistant rats improved glucose homeosta-
sis (Marques et al., 2016b). Also, GABA suppletion can positively
affect insulin sensitivity in rodents (Tian et al., 2011), which may
relate to the beneficial effects on Rd. Based on the small sample
size, however, we refrained from associating changes in plasma
metabolites with Rd in our study.
Short-Term Effects of Lean Donor FMT: Responders
versus Non-responders
Although at 6 weeks an overall significant improvement in pe-
ripheral insulin sensitivity was observed in the whole allogenic
Cystathione
PGA2

































Figure 3. Changes in Microbiota Species and Plasma Metabolites after Autologous and Allogenic FMT
(A and B) The spider plot depicts a panel of bacterial species that significantly differentiate between autologous and allogenic treatment group, based on the
changes in duodenal (A) and fecal (B) microbial composition 6 weeks after FMT. The axis of the spider plot reflects the amount of change (L2 norm) of the bacterial
species upon autologous (red) or allogenic (green) FMT.
(C) Importance plot showing significant associations between changes in fasting plasma metabolites between weeks 0 and 6 and either autologous or allogenic
FMT. Plasma metabolites are depicted on the y axis. Weights per metabolite are expressed on the x axis: a positive weight (n = 17) represents an association
with allogenic lean donor feces treatment, whereas a negative weight (n = 13) represents an association with autologous feces treatment. The higher the weight,
the stronger the association.
FMT, fecal microbiota transplantation; iPF, isoprostane F; LPA, lysophosphatidic acid; PGA, prostaglandin A2; PGF, prostaglandin F.FMT group, a large variation in treatment efficacy was seen
(Figures 2E and 2F), in line with earlier results reporting an inter-
session coefficient of variance (CV) of 10% in Rd (Vrieze et al.,
2012; Reijnders et al., 2016). We therefore split the allogenic
FMT-treated subjects into a group with an Rd increase R10%
(responders, n = 13) and a group with an Rd increase <10%
(non-responders, n = 13) between weeks 0 and 6. Within the
responder group, both peripheral (median Rd from 29.9 [17.9–
36.4] to 36.4 [25.3–41.3] mmol$kg1$min1, p < 0.01) and hepatic
insulin sensitivity (median insulin-mediated EGP suppression
from 54.9% [44.7–64.4] to 63.5% [48.5–68.8], p < 0.05)
increased significantly, whereas in the non-responder group no
effect was seen. Weight did not change in either of the two
groups. Within the responders, we observed a significant
change in fecal abundance of Akkermansia muciniphila (Figures
4A and 4B), which has been linked to beneficial metabolic effects
in targeted intervention studies in both rodents and humans
(Shin et al., 2014; Dao et al., 2016). Moreover, our findings of
alterations in SCFA-producing bacteria from the genus Eubacte-
rium in relation to changes in insulin sensitivity are in line with
findings in large cohorts of insulin-resistant subjects (Forslund
et al., 2015; Dao et al., 2016). In contrast, the genus Roseburia
was previously shown to be negatively correlated with an insu-
lin-resistant state (Forslund et al., 2015), which is in contrast to
our observation of overall decreased presence of this bacterial
strain despite improved glucose regulation upon allogenic
FMT. No significant changes were observed in Shannon’s diver-
sity index after allogenic FMT (responders from 5.8 [5.8–5.9] to
6.0 [5.8–6.1] versus non-responders from 6.0 [6.0–6.2] to 6.0
[5.9–6.1], n.s.) (Figure 5A).
Finally, we determined if fecal microbiota composition at
baseline would be able to predict the responder or non-
responder status upon lean donor allogenic FMT. With a good
prediction (receiver operating characteristic [ROC] AUC 0.88;
Figure 5B), we found that metabolic responders were character-ized by lower initial fecal microbiota diversity (Figure 5A). This
was combined with higher abundance of Subdoligranulum
variabile and Dorea longicatena in comparison to non-re-
sponders, whereas abundance of Eubacterium ventriosum and
Ruminococcus torques was lower in baseline fecal samples of
responders (Figure 5C). Our findings thus confirm that lower
fecal microbial diversity at baseline is predictive of metabolic
improvement upon treatment (Cotillard et al., 2013; Le Chatelier
et al., 2013). We also identified that the majority of the predictive
fecal microbiota comprised abundance of four different species.
In line with previous reports on metabolic response upon dietary
intervention, our responders were characterized by increased
pre-treatment abundance of Subdoligranulum variabile (Chum-
pitazi et al., 2014). In contrast, the increased abundance of the
species Ruminococcus torques in the baseline fecal samples
of non-responders has been previously linked to adverse intesti-
nal health (Png et al., 2010) and aberrant production of (fatty acid
chain-containing) metabolites (Druart et al., 2014). Based on
these findings, we conclude that for future interventions, deter-
mining baseline fecal microbiota composition might aid in
predicting efficacy of treatment.
Limitations
Our study has some limitations. First, we chose to closely
monitor caloric intake while keeping the regular diet of each
study subject, as the introduction of a standardized diet influ-
ences gut microbiota composition (Zeevi et al., 2015). This could
have influenced the impact of the FMT success. Second, our
study was performed in male obese Caucasian subjects,
possibly precluding generalization of our findings to other patient
groups. Third, we used multiple fecal donors, which might
explain the transient and variable effects seen in Rd upon
allogenic FMT at 6 and 18 weeks. However, using one fecal
donor was logistically not possible as we used fresh feces and
















Figure 4. Changes in Fecal Microbiota Composition between Responders and Non-responders
(A) Biplot of redundancy analysis (RDA axis 1 versus axis 2) of fecal microbiota data, constrained by response and non-response variables in time (0 and 6weeks).
Response is defined by the Rd change 6 weeks after allogenic FMT, either R10% increase (responders) or <10% increase (non-responders).
(B) Spider plot of bacterial species that significantly differentiate between responders and non-responders, based on the changes in fecal microbial composition
6 weeks after allogenic FMT. The axis of the spider plot reflects the amount of change (L2 norm) of the bacterial species in the responder (red) and non-responder
(green) groups. Response is defined by the Rd change 6 weeks after allogenic FMT, either R10% increase (responders) or <10% increase (non-responders).
FMT, fecal microbiota transplantation; Rd, rate of (glucose) disappearance.regarding matching criteria that would justify fecal donor stratifi-
cation. Moreover, due to ethical constraints we were only
allowed to determine Rd on three occasions, whereas in hind-
sight having a 12-week time point would have been a valuable
addition. Nevertheless, our intervention study provides further
evidence on the involvement of gut microbiota in human insulin
resistance as single allogenic FMT (without previous antibiotic
intestinal decontamination) resulted in a significant, short-term,
beneficial therapeutic effect. Moreover, we were able to showA B
Figure 5. Fecal Bacterial Diversity and Bacterial Strains in Baseline Fe
(A) Shannon diversity index at weeks 0 and 6 for both Rd responders and non-re
differences (p < 0.05) are depicted.
(B) ROCof themodel trained to predict response (Rd increaseR10%at 6weeks a
(C) Bacterial species in baseline fecal samples that predict metabolic response are
fecal sample of metabolic syndrome subjects that significantly can predict metabo
at 6 weeks is shown. On the y axis baseline relative abundance of each identifie
FMT, fecal microbiota transplantation; Rd, rate of (glucose) disappearance traine
or non-responders (<10% Rd increase) based on baseline fecal microbiota com
616 Cell Metabolism 26, 611–619, October 3, 2017that the overall lack of long-term clinical effect (e.g., improve-
ments in insulin sensitivity) was associated with return to
baseline of both intestinal microbiota and plasma metabolites.
Conclusion
In conclusion, our data underscore the potential role of in-
testinally produced metabolites as (signaling) molecules and
drivers of insulin sensitivity and underscore previous sugges-
tions that pre-treatment fecal microbiota signatures mightC
cal Samples Related to Metabolic Response
sponders is shown. Data are expressed as box-and-whisker plots. Significant
fter allogenic FMT) based on baseline fecal microbiota composition is depicted.
shown. The bar plots each depict a panel of 11 bacterial species in the baseline
lic response upon allogenic FMT at 6 weeks. On the x axis metabolic response
d fecal bacterial species (L2 norm) is shown.
d to predict responders (Rd increase R10% at 6 weeks after allogenic FMT)
position; AUC, area under the curve; ROC, receiver operating characteristic.
regulate engraftment of (lean-donor-derived) bacterial species
and thus predict treatment success (Cotillard et al., 2013; Li
et al., 2016). Disentangling such a specific signature of intestinal
microbiota involved in beneficial functional (metabolic) shifts
might help to apply approaches aiming to better predict
development of insulin resistance and design targeted micro-
biota-based interventions in obese humans.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study Subjects
Male, omnivorous, Caucasian, obese subjects were recruited by newspaper advertisement and screened for characteristics of the
metabolic syndrome. We included adult (age 21-69 years.) Caucasian males, who had obesity (body mass index (BMI)R 30 kg/m2),
fulfilled the National Cholesterol Education Program (NCEP)-criteria for metabolic syndrome (R3/5: fasting plasma glucose R
5.6 mmol/l, triglycerides R 1.7 mmol/l, waist-circumference > 102 cm, high-density lipoprotein (HDL-)cholesterol < 1.03 mmol/l,
blood pressureR 130/85 mmHg), were treatment naive and who where otherwise healthy. Exclusion criteria were a history of recent
weight loss, cardiovascular event, cholecystectomy and the use of any medication known to influence gut microbial composition in
the last three months (including proton pump inhibitors, antibiotics and pre-/pro-/synbiotics) or targeting metabolic diseases (e.g.,
lipid-lowering, anti-diabetic and/or anti-hypertensive drugs).
Lean (BMI < 25 kg/m2), omnivorous, healthy Caucasian males were also recruited by newspaper advertisements to serve as fecal
donors. They completed questionnaires regarding dietary and bowel habits, travel history, comorbidity including (family history of)
diabetes mellitus and medication use. Donors were screened for the presence of infectious diseases as previously published
(van Nood et al., 2013). Blood was screened for presence of (antibodies to) human immunodeficiency virus; human T-lymphotropic
virus; Hepatitis A, B, and C; cytomegalovirus (CMV); Epstein–Barr virus (EBV); strongyloides; amoebiasis and lues. Presence of
infection resulted in exclusion, although previous, non-active infections with EBV and CMVwere allowed. Donors were also excluded
if screening of their feces revealed the presence of pathogenic parasites (e.g., blastocystis hominis, dientamoeba fragilis, giardia
lamblia), bacteria (Shigella, Campylobacter, Yersinia, Salmonella, enteropathogenic E. coli and Clostridium difficile) or viruses
(noro-, rota-, astro-, adeno (40/41/52)-, entero-, parecho- and sapovirus) at AMC department of Clinical Microbiology and Virology.
Written informed consent was obtained from all subjects. The study was approved by the local Institutional Review Board of the
Academic Medical Center (AMC) in Amsterdam, the Netherlands, and conducted at the AMC in accordance with the Declaration of
Helsinki. The study was registered at the Dutch Trial Register (number 2705).
METHOD DETAILS
We performed a double-blind randomized controlled trial (using computerized randomization) with male obese metabolic syndrome
subjects. We studied the effect of allogenic (lean donor) gut microbiota infusion on metabolism in relation to intestinal microbiota
composition 6 and 18 weeks after treatment, using autologous infusion as the control (placebo) treatment. Donors and recipients
were randomly matched. In case a metabolic syndrome subject was randomized for 2 allogenic FMTs, the same selected lean donor
provided the fecal sample for both FMTs.
Study Design
Participants were allowed to keep their own diet, but were asked to keep an online nutritional diary (http://www.eetmeter.nl/) to
monitor daily caloric intake for seven days before each study week. During the 48 hours before the visits in weeks 0, 6 and 18,
subjects collected 24h feces twice and stored this at home. In each study week, three successive study days were preceded by
an overnight fast (Figure S4).
Study Day 1: Mixed Meal Test
The mixed meal test (MMT) started with insertion of an intravenous catheter in a distal arm vein, after which a baseline blood sample
was drawn. After the baseline blood withdrawal, including fasting glucose, HbA1c, lipids and metabolites, subjects immediately
ingested a standardized meal within 5 minutes. This meal contained 616 kCal (2.6 MJ), of which the energy content consisted outCell Metabolism 26, 611–619.e1–e6, October 3, 2017 e2
of 66% fat, 33% carbohydrates and 6% proteins (Reijnders et al., 2016). Start of ingestion was considered T = 0h and the following
4 hours, a blood sample was withdrawn for post-prandial metabolism (e.g., glucose, triglycerides, bile acids, enteroendocrine
hormones) every 30 minutes. The blood samples were stored at 80C.
Study Day 2: Two-Step Hyperinsulinemic Euglycemic Clamp Test and REE
Insulin sensitivity was measured during two-step hyperinsulinemic euglycemic clamp studies. We used [6,6-2H2]glucose (> 99%
enriched; Cambridge Isotopes, Andover, MA, USA) as tracer. After an overnight fast, catheters were inserted into a distal vein of
both arms. One catheter was used for infusion of the glucose tracer, glucose and insulin, while the other was used for sampling
of arterialized venous blood using a heated-hand box (60C), respectively. At T =2h a blood sample was withdrawn for background
enrichment, after which a continuous infusion of [6,6-2H2]glucose (bolus 11 mmol kg
1; continuous 0.11 mmol kg1min1) was started
and continued until the end of the experiment. After 2 hours of equilibration (T = 0h) blood samples (n = 3, every 5minutes) were drawn
for isotope enrichments, glucoregulatory hormones and free fatty acid concentration. Directly thereafter, infusion of insulin
(Actrapid; Novo Nordisk Farma, Alphen aan de Rijn, the Netherlands) was started at a rate of 20 mU m2 min1, meaning the start
of step 1. Plasma glucose was measured every 10 minutes and 20% glucose enriched with 1% [6,6-2H2] glucose (to approximate
plasma enrichment) was infused at a variable rate to maintain plasma glucose at 5.0 mmol l 1. After 2 hours of insulin infusion
(T = 2h), 5 repetitive blood samples were withdrawn every 5 minutes for glucose enrichments, gluco-regulatory hormones and
free fatty acid concentrations. Hereafter, insulin infusion rate was increased to 60 mU m2 min1 for the second step. At T = 4h
another 5 blood samples were withdrawn as describe. Blood samples were stored at 80C for later analyses. Resting energy
expenditure (REE), carbohydrate- and fat oxidation were measured using indirect calorimetry during the basal and hyperinsulinemic
state. Subjects also provided a fecal sample for gut microbiota and short chain fatty acid (SCFA) analysis on either day 1 or 2, and the
sample was immediately frozen and stored at 80C.
Study Day 3: Duodenal Biopsies with/without FMT
At the third study day, subjects reported to the gastroenterology ward in a fasting state for a gastroduodenoscopy followed by FMT
according to a previously described procedure (Vrieze et al., 2012; van Nood et al., 2013). During the endoscopy procedure, we
obtained duodenal biopsies, immediately collected in sterile tubes, snap-frozen in liquid nitrogen and afterward stored at 80C,
followed by positioning of a nasoduodenal tube. The position of the tube was assured by an abdominal X-ray immediately after
the procedure. After ascertaining just placement of the tube, bowel lavage started with infusion of dissolved macrogol/elektrolytes
(Klean-Prep) via the tube at a rate of one liter/hour, until the gastro-intestinal tract was cleaned of fecal content. A maximum of 4 l of
Klean-Prep was used. Prior to the duodenoscopy, every subject as well as the assigned lean donor provided fresh morning feces. At
that moment subjects were randomized in a double-blind fashion to either allogenic (from lean male donors) or autologous (from own
collected feces) FMT (Vrieze et al., 2012; van Nood et al., 2013). Based on the randomization procedure, the designated fecal sample
was used within 6 hours after production for further processing by homogenizing the fecal sample with 500cc 0.9% sterile saline and
filtering this solution through a metal sieve. The solution was stored in a sterile glass 500cc bottle. After the laxation procedure was
completed, a total of 500ml of dissolved fecal content was inserted via the nasoduodenal tube.
All procedures were repeated after 6 weeks to study short-term effects of allogenic FMT. Thereafter, a randomized subgroup of
patients received a second allogenic FMT (from the same lean donor) whereas the other subjects did not receive additional FMT.
All subjects were studied for long-term effects of (either single or double) FMT at 18 weeks, repeating all aforementioned study
procedures.
Sample Analyses
Fasting plasma lipids, including total cholesterol, low-density lipoprotein (LDL-) cholesterol, high-density lipoprotein (HDL-)
cholesterol and triglycerides, were analyzed using commercially available assays (Diasys, Waterbury, Connecticut, USA) on a Selek-
tra autoanalyser system (Sopachem, Ochten, the Netherlands). Plasma glucose and triglycerides were measured both pre- and
during four hours post-prandially, in samples from the MMTs. Fasting plasma metabolites were determined by liquid chromatog-
raphy-mass spectrometry (LC-MS) for a panel of 96 metabolites containing amino acids, oxidative stress markers and lipids as pre-
viously described (Hu et al., 2008; Noga et al., 2012; Fu et al., 2016).
Enteroendocrine Hormones
Plasma concentrations of the enteroendocrine hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like
peptide-1 (GLP-1) and peptide YY (PYY) were determined as previously described (Plamboeck et al., 2013), using pre- and post-
prandial plasma samples from the MMTs. In short, plasma was treated with 70% ethanol (final concentrations) before analysis by
RIA. PYY was measured using a mid-region specific antibody, code no. HYB 347-07 (Statens Serum Institut, Copenhagen,
Denmark). Total GLP-1 was assayed using antiserum 89390, which has an absolute requirement for the intact amidated C terminus
of themolecule. Intact GIPwasmeasured using N-terminally directed antisera code nos 98171. Sensitivities were below 2 pmol/l and
intra-assay coefficients of variation better than 6% (Krarup and Holst, 1984; Plamboeck et al., 2005).
Bile Acids
Plasma bile acid concentrations as well as bile acid levels in 24h. feces were determined by mass spectrometry (respectively liquid
chromatography-tandemmass spectrometry (LC-MS/MS)) or gas chromatography (GC)-MS). Plasma bile acid concentrations were
determined in 25 ml homogenized plasma, using pre- and post-prandial plasma samples from the MMTs. For sample preparation,
250 ml internal standard solution containing D4-cholate, D4-chenodeoxycholate, D4-glycocholate, D4-taurocholate, D4-glycocheno-
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was transferred into a new vial. The supernatant was evaporated under nitrogen at 40C. Bile acids were reconstituted in 100 ml 50%
methanol and filtered with a 0.2 mm centrifugal filter at 3000 g. After this step, 10 ml sample was injected into the LC-MS/MS system.
Fecal bile salt composition was analyzed in 24h. feces, for which subjects provided 24h. feces twice and we used the average re-
sults of both days. In short, 50mg of dried feceswas boiled in 1ml of alkalinemethanol (1MNaOH-methanol, 1:3 vol/vol) at 80C for 2h
after addition of 50nmol 5-cholestane and 14nmol 7,12-dihydroxy-5-cholanic acid as internal standard for neutral sterols and bile
salts, respectively. After cooling down to room temperature, neutral sterols were extracted by using 3 3 3 mL of petroleum ether,
boiling range 60 – 80C. The residual sample was diluted 1:9 with distilled water. A sample (100 ul) of the solution was subjected
to an enzymatic total bile salt measurement (Mashige et al., 1976). The remaining solution was used for bile salt isolation by
reversed-phase solid-phase (C18) extraction (Mashige et al., 1976). The eluate was evaporated to dryness, and bile salts were deriv-
atized to themethyl ester-trimethylsilyl derivatives for gas chromatography analysis. The extracted neutral sterols were derivatized to
the trimethylsilyl derivatives by applying the same procedure that was used for bile salts. Bile salt composition of prepared fecal sam-
ples were determined by capillary gas chromatography on an Agilent gas chromatograph (HP 6890), equipped with a 25 m 0.25 mm
CP-Sil-19-fused silica column (Varian, Middelburg, the Netherlands) and a flame ionization detector. The conditions were as follows:
injector temperature 280C; pressure 16.0 psi; column flow constant at 0.8 ml/min; oven temperature program: 240C (4 min),
10C/min to 280C (27 min); detector temperature 300C.
SCFAs
Fasting plasma levels of acetate, propionate and butyrate were determined in plasma samples, obtained at the MMT, using LC-MS,
with minor modifications of the original method (van Eijk et al., 2009).
High-performance liquid chromatograpy (HPLC) analysis on fresh frozen stool samples for fecal SCFA determination was carried
out according to the method from De Baere et al. (2013) with some modifications. Sets of 20 patient samples and 8 external calibra-
tion points including succinic acid as the internal standard (IS) were measured. All SCFA calibrator points and internal standard were
prepared in milli-Q water. A 50 mM stock solution of the SCFA’s containing acetic acid (AA), propionic acid (PA) and butyric acid (BA)
wasmade, aliquoted and stored at20Cuntil analysis. For the calibration curve double dilute series ranging from 25 – 0.39mmwere
prepared and to each calibration point 50 ul of IS (0.4 M) was added. The SCFA’s from the patient samples were extracted from a
200-300 mg fecal sample. In brief, 1 mL Milli-Q Water was added, together with 50ml of IS, after which the samples were vortexed.
100 ml of 12M HCl was added to all samples and calibration steps, after which they were vortexed for 15 s. Subsequently all samples
were extracted twice with 7.5 mL di-ethylether for 20 minutes, centrifuged at 2000 g for 5 minutes and finally the supernatant was
transferred into a clean 30 mL tube and 500ml of 1M NaOH was added. The aqueous phase (bottom) was then transferred to a
new tube and 100 ml of 37% HCl (12M) was added and vortexed. A 300 ml sample was pipetted into a vial insert applicable for the
HPLC autosampler. Of each sample 5 ml was injected for HPLC analysis. The SCFA content was calculated by referring the
SCFA/IS peak ratio to the standard curve. The SCFA concentration was expressed in mmol/g feces. Separation of the SCFA was
carried out on a Hypersil Gold aQ column (150 mm 3 4.6 mm, dp: 3 mm) using a Jasco quaternary pump (PU4285, Jasco Benelux,
DeMeern, the Netherlands) at 30C. Variable flow conditions were applied for the phosphate/acetonitrile gradient. UV detection was
done at 210 nm using a Jasco UV detector (UV4075, Jasco Benelux, De Meern, the Netherlands). All samples were stored in a Jasco
autosampler (AS4285, Jasco Benelux, De Meern, the Netherlands) at 4C until analysis.
Insulin Sensitivity and REE
Plasma enrichment of [6,6-2H2]glucose (tracer-to-tracee ratio), in samples obtained during the 2-step hyperinsulinemic euglycemic
clamp tests, was determined by gas chromatography-mass spectrometry as previously described (Ackermans et al., 2001). Rate of
appearance and rate of disappearance (Rd) of glucose were calculated using the modified version of the Steele equations for both
steady-state (basal) and non–steady-state (during insulin infusion) measurements (Steele, 1959). EGP was calculated as the
difference between the rate of appearance of glucose and the glucose infusion rate and expressed as mmol kg-1min-1. Hepatic insulin
sensitivity was determined by calculating the percentage suppression of basal EGP during the first step of hyperinsulinemia. Periph-
eral insulin sensitivity, expressed as Rd, was determined during the second step of hyperinsulinemia.
Resting energy expenditure (REE) was measured using indirect calorimetry. Oxygen (O2) consumption (VO2) and carbon dioxide
(CO2) production (VCO2) were measured in the supine position during the basal and second step of hyperinsulinemia for 20 minutes
using a ventilated hood system (Vmax Encore 29; SensorMedics, Anaheim, CA, USA). REE including carbohydrate and fatty acid
oxidation were calculated as described previously (Frayn, 1983). The abbreviated Weir equation was used to calculate 24-hour
energy expenditure (Weir, 1949).
Intestinal Microbiota
DNA from fecal samples was isolated using a combination of Repeated-Bead-Beating (RBB) and column purification, described in
detail elsewhere (Salonen et al., 2010). Concentration and purity were assessed with a Nanodrop 1000 spectrophotometer (Thermo
Fisher Scientific, Wilmington, North Carolina, USA). The microbial compositon was determined using a previously described and
benchmarked custom made, phylogenetic microarray, the Human Intestinal Tract Chip (HITChip; Data S1) (Rajilic-Stojanovic
et al., 2009). This is a custom-made Agilent microarray (Agilent Technologies, Palo Alto, CA, USA) containing approximately 5,500
specific oligonucleotide probes. In short, the full-length 16S rRNA gene was amplified, transcribed into RNA, labeled with the
fluorescent dyes, Cy3 and Cy5 and hybridized to the array. Each sample was hybridized twice with a Pearson correlation
of > 0.98 between replicates to ensure reproducibility and raw signal intensities were normalized as previously described (LahtiCell Metabolism 26, 611–619.e1–e6, October 3, 2017 e4
et al., 2014). With some small adjustments, e.g., use of a more suitable reverse primer (Prok-1369-rev instead of Uni-1492-rev) and
use of an accustart polymerase (Vrieze et al., 2012), a similar method was used to determine microbiota abundance in duodenal
biopsies.
The HITChip microarray (Data S1) can detect 1,033 species-like bacterial phylotypes (level 3, > 98% 16S rRNA gene sequence
similarity) that represent the majority of the microbial diversity in the human intestine. These were summarized to 130 genus-like
phylogenetic groups (level 2, > 90%16S rRNAgene sequence similarity) referred to as species and relatives (‘et rel.’). The level 3 anal-
ysis may suffer from cross-hybridization issues, but has been used in several other studies to provide insight at the deepest possible
level, as the analysis depth is comparable to approximately 200,000 16S rRNA reads with next generation sequencing (Claesson
et al., 2009; Jalanka-Tuovinen et al., 2011).
Diversity of the microbiota was quantified based on non-logarithmized HITChip oligo-level signals by inverse Simpson’s and
Shannon’s index using the Vegan package (Oksanen, Package ‘vegan’. Community ecology package, version 2013). Probes
were counted in each sample to measure richness by using an 80% quantile threshold for detection.
QUANTIFICATION AND STATISTICAL ANALYSIS
Our (hierarchical) hypothesis was that at 6weeks after allogenic (lean donor) FMT, the peripheral insulin sensitivity (Rd) would improve
by 5 mmol kg-1 min-1 (with a standard deviation of 4 mmol kg-1 min-1). Moreover, we also aimed to study whether a second lean donor
FMT at 6 weeks, on top of the first treatment, would maintain this 5 mmol kg-1 min-1 increase in Rd at 18 weeks. We expected that no
extra treatment at 6 weeks (thus only single allogenic FMT at baseline) would result in Rd-levels at 18 weeks similar to baseline
Rd-levels (exploratory analyses). With a randomization ratio of 2:1, the sample size should be 24 metabolic syndrome subjects
treated with allogenic FMT, whereas we would need 12 metabolic syndrome subjects treated with autologous (own) FMT. Taking
a dropout of 20% in each treatment arm into account, we aimed to include 45metabolic syndrome subjects in total. With this sample
size, the study has > 80% power in a 2-sided test with a = 0.05.
Primary endpoint of the trial was the change in intestinal microbiota composition upon FMT in relation to insulin sensitivity. Other
endpoints were changes in post-prandial lipid and glucose excursions, as well as plasma metabolites. A non-Gaussian distribution
for all clinical data was assumed, and thus results are presented as medians and interquartile ranges. Post-prandial results (e.g., for
plasma glucose, triglycerides, bile acids and enteroendocrine hormones) are described as (incremental) area under the curves (iAUC)
for the 4 hour post-prandial follow-up, calculated by using the trapezoidal method.
Statistical testing was carried out using non-parametric tests. For between-group comparisons, either the Mann-Whitney U test or
Kruskal-Wallis test was used. Friedman or Wilcoxon signed rank test was used for within-group comparisons of repeated-measure-
ments. A false discovery rate corrected p value below 0.05 was considered significant, corrected for multiple testing in case of
microbiota and metabolite data, as described underneath.
Multivariate Machine Learning Analysis
To study dynamics of biomarkers, e.g., species-level microbiota (level 3) and fasting metabolites, we computed the relative change
for each individual subject over time. The relative change is, for example, the difference inmicrobial abundance between baseline and
6 weeks, divided by the microbial abundance at baseline, computed for each bacterial species per subject. In case of the microbiota
analysis, this resulted into three datasets: 1) relative change in duodenal microbial composition of the allogenic and autologous
treatment groups; 2) relative change in fecal microbial composition of the allogenic and autologous treatment groups; 3) relative
change in fecal microbial composition of the responder and non-responder subjects. To assess the amount of change in intestinal
microbial composition for each subject, we computed the magnitude of change by using L2 norm (Meyer, 2000). Informally, L2
(or Euclidian) norm is a measure of the vector length that is computed via calculating the sum of squared values of the relative
differences of all species (between baseline and 6 weeks) per subject. The final result is calculated by taking the square root of
the obtained value.
Biomarkers that allowed accurate discrimination among groups of subjects (allogenic versus autologous, responders versus
non-responders) were selected by means of the elastic net algorithm (Zou and Hastie, 2005). Elastic net method is particularly
applicable for the analysis of structured and high-dimensional data. It is a regularized method that combines the advantages of
two techniques: LASSO (Tibshirani, 1996) (with variable selection property of reducing coefficients to zero values) and ridge regres-
sion (with shrinking coefficients to values for ‘correlated trending’ toward each other). This combination allows for the selection of the
most important biomarkers, while taking the correlation (so called ‘grouping effect’) among them into account. Furthermore, by
imposing an L1-penalty on the coefficients we obtained an interpretable model and viewed non-zero coefficients as the predictors
that have the strongest predictive power. We used an adapted version of the elastic net algorithm (with Hinge loss function), which is
specifically tailored for identification of the most important biomarkers (e.g., microbial species and metabolites) in the collected
dataset, that jointly have an effect on differentiating between allogenic and autologous subjects as well as responders and non-re-
sponders. We trained the model by taking the gradient of the loss that is estimated at each sample at a time (stochastic gradient
descent learning). Our statistic learning approach also includes stability selection (Meinshausen and B€uhlman, 2010). While the
biomarkers identified by elastic net algorithm usually lead to statistically significant results, they can frequently be unstable. In our
approach, we address this problem via stability selection procedure (Meinshausen and B€uhlman, 2010) coupled with the model
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re-randomized dataset. This procedure is especially relevant for small- tomedium-sized data collections as recently published by our
group (Botschuijver et al., 2017).
To avoid over-fitting, we used a 10-fold stratified cross-validation procedure over the training partition of the data (80%) while the
remaining 20% was used as the testing dataset. Parameters to be selected are ratio between L1, L2 norms, and regularization
threshold. Stability selection was performed by randomly subsampling 80% of the data 100 times. During stability selection proced-
ure, all features having non-zero weight coefficient were counted. These counts were normalized and converted to stability
coefficients having value between 1.0 for the feature that was always selected and 0.0 for feature which was never selected. We
used Python (version 2.7.8, packages Numpy, Scipy) for implementing elastic net model and R (version 3.1.2) for visualization.
A randomization test was conducted to evaluate the statistical validity of the results obtained via elastic net algorithm. We followed
the procedure where the outcome variable (e.g., allogenic versus autologous or responder versus non-responder) was randomly
reshuffled while the corresponding microbial profiles were kept intact. This was repeated up to 100 times and Receiver-Oper-
ating-Characteristics Area-Under-Curve (ROC AUC) scores were computed each time. The performance measure used for a binary
classification task is a ROC AUC. The ROC can be understood as a plot of the probability of correctly classifying allogenic versus
autologous treated subjects or responders versus non-responders. Cross-validation within the dataset was accomplished by
randomly hiding 20% of the subjects from the model and evaluating the prediction quality on that group. The ROC AUC score mea-
sures the predictive accuracy of the classification model with 0.5 AUC corresponding to a random result. A critical value of 0.05 was
defined and the true AUC of the original dataset was compared with this value.
To visualize and study correlations among the subjects at different time points we used Redundancy analysis (RDA) (van den
Wollenberg, 1977). RDA can be considered as a constrained version of principal components analysis (PCA), where the canonical
axes are built from linear combinations of the response variables. RDA extends multiple linear regression by allowing regression
of the response variables on multiple explanatory variables. Furthermore, to analyze the biomarkers of the subjects an unsupervised
co-regularized spectral clustering algorithmwas applied to the dataset (Tsivtsivadze et al., 2013; Biesbroek et al., 2014). In short, this
multi-view clustering algorithm allows identification of clusters with similar microbial and metabolite profiles in an unbiased and
robust manner. The method stems from a recently proposed class of multi-view clustering algorithms (Kumar et al., 2011) that
have been reported to notably outperform standard techniques (e.g., k-means, hierarchical clustering, etc.) in accuracy and stability.
Multi-view algorithms (closely related to cluster ensembles and consensus techniques) aim to combine multiple clustering
hypotheses for increased accuracy and are not limited to a single similarity measure, thus leading to robust and reliable results.Cell Metabolism 26, 611–619.e1–e6, October 3, 2017 e6
